Claims
- 1. A method for obtaining optimized EPO dosage regimens for a desired pharmacodynamic response in a patient comprising the steps of:
(a) choosing one or more EPO dosage regimens; (b) using a pharmacokinetic/pharmacodynamic model to determine the pharmacodynamic profile of said one or more EPO dosage regimens; and (c) selecting said one or more EPO dosage regimens that provide said desired pharmacodynamic response based on said pharmacodynamic profile.
- 2. The method of claim 1, wherein said pharmacodynamic response comprises of one or more of the group consisting of reticulocyte number, RBC number, and hemoglobin level.
- 3. The method of claim 1, wherein said patient is anemic.
- 4. The method of claim 3, wherein said anemia comprises EPO concentration related anemia.
- 5. The method of claim 4, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 6. The method of claim 4, wherein said anemia comprises cancer chemotherapy related anemia.
- 7. The method of claim 4, wherein said anemia comprises AIDS drug therapy related anemia.
- 8. The method of claim 4, wherein said anemia comprises drug related anemia.
- 9. The method of claim 8, wherein said drug include cisplatin and zidovudine.
- 10. The method of claim 1, wherein said patient is undergoing autologous transfusion prior to surgery.
- 11. The method of claim 1, wherein said patient is recovering from allogenic bone marrow transplant.
- 12. The method of claim 1, wherein said patient is afflicted with rheumatoid arthritis.
- 13. The method of claim 1, wherein said dosage regimens are subcutaneous dosage regimens.
- 14. A method for obtaining optimized EPO dosage regimens for a desired pharmacodynamic response in a patient comprising the steps of:
(a) selecting one or more desired pharmacodynamic responses; (b) using a pharmacokinetic/pharmacodynamic model to determine EPO dosage regimens that provides said desired one or more pharmacodynamic responses; and (c) selecting the one or more EPO dosage regimens that provide said desired pharmacodynamic responses.
- 15. The method of claim 14, wherein said pharmacodynamic response comprises of one or more of the group consisting of reticulocyte number, RBC number, and hemoglobin level.
- 16. The method of claim 14, wherein said patient is anemic.
- 17. The method of claim 16, wherein said anemia comprises EPO concentration related anemia.
- 18. The method of claim 17, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 19. The method of claim 17, wherein said anemia comprises cancer chemotherapy related anemia.
- 20. The method of claim 17, wherein said anemia comprises AIDS drug therapy related anemia.
- 21. The method of claim 17, wherein said anemia comprises drug related anemia.
- 22. The method of claim 21, wherein said drug include cisplatin and zidovudine.
- 23. The method of claim 14, wherein said patient is undergoing autologous transfusion prior to surgery.
- 24. The method of claim 14, wherein said patient is recovering from allogenic bone marrow transplant.
- 25. The method of claim 14, wherein said patient is afflicted with rheumatoid arthritis.
- 26. The method of claim 14, wherein said dosage regimens are subcutaneous dosage regimens.
- 27. A system for selecting an optimal EPO dosage regimens for a patient using a pharmacokinetic/pharmacodynamic model comprising:
(a) a processor that is controlled in accordance with a set of program instructions that determine the steps implemented by said pharmacokinetic/pharmacodynamic model; (b) a memory coupled to said processor, said memory storing the set of program instructions and parameters used by said pharmacokinetic/pharmacodynamic model; and (c) a user interface, coupled to said processor, said user interface enabling a user to input parameters used by said pharmacokinetic/pharmacodynamic model.
- 28. The method of claim 27, wherein said pharmacodynamic response comprises of one or more of the group consisting of reticulocyte number, RBC number, and hemoglobin level.
- 29. The method of claim 27, wherein said patient is anemic.
- 30. The method of claim 29, wherein said anemia comprises EPO concentration related anemia.
- 31. The method of claim 30, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 32. The method of claim 30, wherein said anemia comprises cancer chemotherapy related anemia.
- 33. The method of claim 30, wherein said anemia comprises AIDS drug therapy related anemia.
- 34. The method of claim 30, wherein said anemia comprises drug related anemia.
- 35. The method of claim 34, wherein said drug include cisplatin and zidovudine.
- 36. The method of claim 27, wherein said patient is undergoing autologous transfusion prior to surgery.
- 37. The method of claim 27, wherein said patient is recovering from allogenic bone marrow transplant.
- 38. The method of claim 27, wherein said patient is afflicted with rheumatoid arthritis.
- 39. The method of claim 27, wherein said dosage regimens are subcutaneous dosage regimens.
- 40. A computer program for obtaining optimized EPO dosage regimens for a desired pharmacodynamic response in a patient comprising:
(a) computer code that describes a pharmacokinetic/pharmacodynamic model for EPO, said code providing for selection of one or more desired pharmacodynamic responses and the use of said pharmacokinetic/pharmacodynamic model to determine one or more EPO dosage regimens that provide said desired one or more pharmacodynamic responses; and (b) computer readable medium that stores said computer code.
- 41. The method of claim 40, wherein said pharmacodynamic response comprises of one or more of the group consisting of reticulocyte number, RBC number, and hemoglobin level.
- 42. The method of claim 40, wherein said patient is anemic.
- 43. The method of claim 42, wherein said anemia comprises EPO concentration related anemia.
- 44. The method of claim 43, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 45. The method of claim 43, wherein said anemia comprises cancer chemotherapy related anemia.
- 46. The method of claim 43, wherein said anemia comprises AIDS drug therapy related anemia.
- 47. The method of claim 43, wherein said anemia comprises drug related anemia.
- 48. The method of claim 47, wherein said drug include cisplatin and zidovudine.
- 49. The method of claim 40, wherein said patient is undergoing autologous transfusion prior to surgery.
- 50. The method of claim 40, wherein said patient is recovering from allogenic bone marrow transplant.
- 51. The method of claim 40, wherein said patient is afflicted with rheumatoid arthritis.
- 52. The method of claim 40, wherein said dosage regimens are subcutaneous dosage regimens.
- 53. A computer program for obtaining optimized EPO dosage regimens for a desired pharmacodynamic response in a patient comprising:
(a) computer code that describes a pharmacokinetic/pharmacodynamic model for EPO, said code providing for user selection of one or more EPO dosage regimens and the use of said pharmacokinetic/pharmacodynamic model to determine a pharmacodynamic response for said one or more rHuEPO dosage regimens; and (b) computer readable medium that stores said computer code.
- 54. The method of claim 53, wherein said pharmacodynamic response comprises of one or more of the group consisting of reticulocyte number, RBC number, and hemoglobin level.
- 55. The method of claim 53, wherein said patient is anemic.
- 56. The method of claim 55, wherein said anemia comprises EPO concentration related anemia.
- 57. The method of claim 56, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 58. The method of claim 56, wherein said anemia comprises cancer chemotherapy related anemia.
- 59. The method of claim 56, wherein said anemia comprises AIDS drug therapy related anemia.
- 60. The method of claim 56, wherein said anemia comprises drug related anemia.
- 61. The method of claim 60, wherein said drug include cisplatin and zidovudine.
- 62. The method of claim 53, wherein said patient is undergoing autologous transfusion prior to surgery.
- 63. The method of claim 53, wherein said patient is recovering from allogenic bone marrow transplant.
- 64. The method of claim 53, wherein said patient is afflicted with rheumatoid arthritis.
- 65. The method of claim 53, wherein said dosage regimens are subcutaneous dosage regimens.
- 66. A method for obtaining optimized EPO dosage regimens for a desired pharmacokinetic response in a patient comprising the steps of:
(a) choosing one or more EPO dosage regimens; (b) using a pharmacokinetic/pharmacodynamic model to determine the pharmacokinetic profile of said one or more EPO dosage regimens; and (c) selecting the one or more EPO dosage regimens that provide said desired pharmacokinetic response based on said pharmacokinetic profile.
- 67. The method of claim 66, wherein said pharmacokinetic response comprises of one or more of the group consisting of serum EPO levels, bioavailablity, and threshold level.
- 68. The method of claim 66, wherein said patient is anemic.
- 69. The method of claim 68, wherein said anemia comprises EPO concentration related anemia.
- 70. The method of claim 69, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 71. The method of claim 69, wherein said anemia comprises cancer chemotherapy related anemia.
- 72. The method of claim 69, wherein said anemia comprises AIDS drug therapy related anemia.
- 73. The method of claim 69, wherein said anemia comprises drug related anemia.
- 74. The method of claim 73, wherein said drug include cisplatin and zidovudine.
- 75. The method of claim 66, wherein said patient is undergoing autologous transfusion prior to surgery.
- 76. The method of claim 66, wherein said patient is recovering from allogenic bone marrow transplant.
- 77. The method of claim 66, wherein said patient is afflicted with rheumatoid arthritis.
- 78. The method of claim 66, wherein said dosage regimens are subcutaneous dosage regimens.
- 79. A method for obtaining optimized EPO dosage regimens for a desired pharmacokinetic response in a patient comprising the steps of:
(a) selecting one or more desired pharmacokinetic responses; (b) using a pharmacokinetic/pharmacodynamic model to determine EPO dosage regimens that provide said desired one or more pharmacokinetic responses; and (c) selecting one or more EPO dosage regimens that provide said desired pharmacokinetic responses.
- 80. The method of claim 79, wherein said pharmacokinetic response comprises of one or more of the group consisting of serum EPO levels, bioavailability, and threshold level.
- 81. The method of claim 79, wherein said patient is anemic.
- 82. The method of claim 81, wherein said anemia comprises EPO concentration related anemia.
- 83. The method of claim 82, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 84. The method of claim 82, wherein said anemia comprises cancer chemotherapy related anemia.
- 85. The method of claim 82, wherein said anemia comprises AIDS drug therapy related anemia.
- 86. The method of claim 82, wherein said anemia comprises drug related anemia.
- 87. The method of claim 86, wherein said drug include cisplatin and zidovudine.
- 88. The method of claim 79, wherein said patient is undergoing autologous transfusion prior to surgery.
- 89. The method of claim 79, wherein said patient is recovering from allogenic bone marrow transplant.
- 90. The method of claim 79, wherein said patient is afflicted with rheumatoid arthritis.
- 91. The method of claim 79, wherein said dosage regimens are subcutaneous dosage regimens.
- 92. A computer program for obtaining optimized EPO dosage regimens for a desired pharmacokinetic response in a patient comprising:
(a) computer code that describes a pharmacokinetic/pharmacodynamic model for EPO, said code providing for selection of one or more desired pharmacokinetic responses and the use of said pharmacokinetic/pharmacodynamic model to determine one or more EPO dosage regimens that provide said desired one or more pharmacokinetic responses; and (b) computer readable medium that stores said computer code.
- 93. The method of claim 92, wherein said pharmacokinetic response comprises of one or more of the group consisting of serum EPO levels, bioavailability, and threshold level.
- 94. The method of claim 92, wherein said patient is anemic.
- 95. The method of claim 94, wherein said anemia comprises EPO concentration related anemia.
- 96. The method of claim 95, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 97. The method of claim 95, wherein said anemia comprises cancer chemotherapy related anemia.
- 98. The method of claim 95, wherein said anemia comprises AIDS drug therapy related anemia.
- 99. The method of claim 95, wherein said anemia comprises drug related anemia.
- 100. The method of claim 99, wherein said drug include cisplatin and zidovudine.
- 101. The method of claim 92, wherein said patient is undergoing autologous transfusion prior to surgery.
- 102. The method of claim 92, wherein said patient is recovering from allogenic bone marrow transplant.
- 103. The method of claim 92, wherein said patient is afflicted with rheumatoid arthritis.
- 104. The method of claim 92, wherein said dosage regimens are subcutaneous dosage regimens.
- 105. A computer program for obtaining optimized EPO dosage regimens for a desired pharmacokinetic response in a patient comprising:
(a) computer code that describes a pharmacokinetic/pharmacodynamic model for EPO, said code providing for user selection of one or more EPO dosage regimens and the use of said pharmacokinetic/pharmacodynamic model to determine a pharmacokinetic response for said one or more EPO dosage regimens; and (b) computer readable medium that stores said computer code.
- 106. The method of claim 105, wherein said pharmacokinetic response comprises of one or more of the group consisting of serum EPO levels, bioavailability, and threshold level.
- 107. The method of claim 105, wherein said patient is anemic.
- 108. The method of claim 107, wherein said anemia comprises EPO concentration related anemia.
- 109. The method of claim 108, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 110. The method of claim 108, wherein said anemia comprises cancer chemotherapy related anemia.
- 111. The method of claim 108, wherein said anemia comprises AIDS drug therapy related anemia.
- 112. The method of claim 108, wherein said anemia comprises drug related anemia.
- 113. The method of claim 112, wherein said drug include cisplatin and zidovudine.
- 114. The method of claim 105, wherein said patient is undergoing autologous transfusion prior to surgery.
- 115. The method of claim 105, wherein said patient is recovering from allogenic bone marrow transplant.
- 116. The method of claim 105, wherein said patient is afflicted with rheumatoid arthritis.
- 117. The method of claim 105, wherein said dosage regimens are subcutaneous dosage regimens.
- 118. A method for creating a pharmacokinetic model for subcutaneous EPO administration in patients comprising the steps of:
(a) obtaining pharmacokinetic data from patients; (b) choosing an equation based on said data; and (c) fitting said pharmacokinetic data to said equation.
- 119. A method for creating a pharmacodynamic model for subcutaneous EPO administration in patients comprising the steps of:
(a) normalizing serum EPO concentrations; (b) obtaining pharmacodynamic data; (c) choosing a pharmacodynamic model; (d) obtaining equation based on said model; and (e) fitting pharmacodynamic data to said equation.
- 120. The method of claim 118, wherein said obtaining pharmacokinetic data comprises:
(a) normalizing serum EPO concentration values from said pharmacokinetic data; and (b) creating serum EPO versus time profiles based on said normalized data.
- 121. The method of claim 120, wherein said normalizing step comprises:
(a) obtaining baseline serum EPO concentration values from said pharmacokinetic data by averaging predose serum EPO concentration values at plurality of time points; (b) obtaining serum EPO concentration values following subcutaneous EPO administration; (c) obtaining normalized serum EPO concentration values by subtracting predose EPO concentration values from serum EPO concentration values; and (d) calculating mean normalized serum EPO concentration values at each time point.
- 122. The method of claim 118, wherein said pharmacokinetic equation comprises the Michaelis-Menten equation.
- 123. The method of claim 118, wherein said fitting step comprises obtaining estimates of pharmacokinetic parameters utilizing least-squares by Maximum Likelihood method and extended least squares model.
- 124. The method of claim 123, wherein said parameters are selected from the group consisting of Vmax, Km, Vd, Ka, Fr, τ (lower doses), and τ (higher dose).
- 125. The method of claim 123, wherein said fitting step comprises utilizing ADAPT II software.
- 126. A method for calculating the bioavailability of EPO following subcutaneous administration comprises the steps of:
(a) obtaining pharmacokinetic data; (b) calculating AUC; (c) normalizing AUC to dose; and (d) deriving an equation to represent said bioavailability of EPO by performing a linear regression of said pharmacokinetic data.
- 127. The method of claim 119, wherein said normalizing step comprises:
(a) obtaining baseline serum EPO concentration (Cbs) for each dose group by averaging predose serum EPO concentration values at plurality of time points for each dose group; and (b) adjusting Cbs by adding Cbs to serum EPO concentration predicted by pharmacokinetic model wherein said adjusted CbS may be used as a forcing function for pharmacodynamic analysis.
- 128. The method of claim 119, wherein said obtaining pharmacodynamic data step comprises:
(a) determining mean predose precursor cell number; (b) determining mean predose reticolucyte number; (c) determining mean predose RBC number; (d) determining mean predose hemoglobin concentration; (e) obtaining mean reticulocyte versus time profiles according to EPO dose; (f) obtaining mean RBC versus time profiles according to EPO dose; and (g) obtaining mean hemoglobin versus time profiles according to EPO dose.
- 129. The method of claim 119, wherein said pharmacodynamic model comprises a cell production and cell loss model.
- 130. The method of claim 119, wherein said fitting step comprises obtaining parameters utilizing least squares by Maximum Likelihood method and extended least squares model.
- 131. The method of claim 130, wherein said parameters comprise estimated parameters and fixed parameters.
- 132. The method of claim 131, wherein said estimated parameters comprise Ks, SC50, and TP.
- 133. The method of claim 131, wherein said fixed parameters comprise RL, RBCL, Hb, and threshold.
- 134. The method of claim 130, wherein said fitting step comprises utilizing ADAPT II software.
- 135. A method for predicting a pharmacodynamic response in a patient to subcutaneous EPO administration comprising the steps of:
(a) selecting EPO dose and dosage regimens; and (b) determining said pharmacodynamic response based on said dose and dosage regimens.
- 136. The method of claim 135, wherein said pharmacodynamic response comprises of one or more of the group consisting of reticulocyte number, RBC number, and hemoglobin level.
- 137. The method of claim 135, wherein said patient is anemic.
- 138. The method of claim 137, wherein said anemia comprises EPO concentration related anemia.
- 139. The method of claim 138, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 140. The method of claim 138, wherein said anemia comprises cancer chemotherapy related anemia.
- 141. The method of claim 138, wherein said anemia comprises AIDS drug therapy related anemia.
- 142. The method of claim 138, wherein said anemia comprises drug related anemia.
- 143. The method of claim 142, wherein said drug include cisplatin and zidovudine.
- 144. The method of claim 135, wherein said patient is undergoing autologous transfusion prior to surgery.
- 145. The method of claim 135, wherein said patient is recovering from allogenic bone marrow transplant.
- 146. The method of claim 135, wherein said patient is afflicted with rheumatoid arthritis.
- 147. The method of claim 135, wherein said dosage regimens are subcutaneous dosage regimens.
- 148. A method for administering EPO comprising the steps of:
choosing one or more EPO dosage regimens using a pharmacokinetic/pharmacodynamic model to determine the pharmacodynamic profile of said one or more EPO regimens; selecting said EPO dosage regimens that provides a desired pharmacodynamic response based on said pharmacodynamic profile; and administering said EPO dosage regimen to a patient.
- 149. The method of claim 148, wherein said EPO dosing regimen comprises administering EPO once a week.
- 150. The method of claim 148, wherein said EPO dosing regimen comprises administering EPO twice a week.
- 151. The method of claim 148, wherein said patient is anemic.
- 152. The method of claim 151, wherein said anemia comprises EPO concentration related anemia.
- 153. The method of claim 151, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 154. The method of claim 151, wherein said anemia comprises cancer chemotherapy related anemia.
- 155. The method of claim 151, wherein said anemia comprises AIDS drug therapy related anemia.
- 156. The method of claim 151, wherein said anemia comprises drug related anemia.
- 157. The method of claim 156, wherein said drug is selected from the group consisting of cisplatin and zidovudine.
- 158. The method of claim 148, wherein said patient is undergoing autologous transfusion prior to surgery.
- 159. The method of claim 148, wherein said patient is recovering from allogenic bone marrow transplant.
- 160. The method of claim 148, wherein said patient is afflicted with rheumatoid arthritis.
- 161. The method of claim 148, wherein said EPO dosage regimens are administered subcutaneously.
- 162. A method of administering EPO comprising the steps of:
selecting one or more desired pharmacodynamic responses; using a pharmacokinetic/pharmacodynamic model to determine EPO dosage regimen that provides said desired one or more pharmacodynamic responses; selecting said one ore more EPO dosage regimens that provides said desired pharmacodynamic responses; and administering said selected EPO dosage regiment to a patient.
- 163. The method of claim 162, wherein said EPO dosage regimen comprises administering EPO once a week.
- 164. The method of claim 162, wherein said EPO dosage regiment comprises administering EPO once every weeks.
- 165. The method of claim 162, wherein said pharmacodynamic responses are selected from the groups consisting of reticulocyte number, RBC number, and hemoglobin level.
- 166. The method of claim 162, wherein said patient is anemic.
- 167. The method of claim 162, wherein said anemia comprises EPO concentration related anemia.
- 168. The method of claim 162, wherein said anemia comprises end-stage renal or renal failure related anemia.
- 169. The method of claim 162, wherein said anemia comprises cancer chemotherapy related anemia.
- 170. The method of claim 162, wherein said anemia comprises AIDS drug therapy related anemia.
- 171. The method of claim 162, wherein said anemia comprises drug related anemia.
- 172. The method of claim 171, wherein said drug is selected from the group consisting of cisplatin and zidovudine.
- 173. The method of claim 162, wherein said patient is undergoing autologous transfusion prior to surgery.
- 174. The method of claim 162, wherein said patient is recovering from allogenic bone marrow transplant.
- 175. The method of claim 162, wherein said patient is afflicted with rheumatoid arthritis.
- 176. The method of claim 162, wherein said EPO dosage regimens are administered subcutaneously.
- 177. A method for administering EPO to a patient comprising the step of:
administering said EPO on a once-weekly basis.
- 178. The method of claim 177, wherein said administering comprises a dose 40,000 IU of said EPO.
- 179. A method for administering EPO to a patient comprising the step of:
administering said EPO on a once every two week basis.
- 180. The method of claim 179, wherein said administering comprises a dose selected from the group consisting of 80,000 IU/kg, 100,000 IU/kg, and 120,000 IU/kg.
- 181. A method for enhancing the production of mature red blood cells from young red blood cells in a patient comprising the step of: administering EPO to said patient so that said young red blood cells are induced to become mature red blood cells.
- 182. A method for maintaining an enhanced level of red blood cells in a patient comprising the step of:
administering a first dose of EPO followed by a second dose of EPO to said patient, wherein said second dose of EPO is administered to said patient at a time after said first dose that coincides with the production of reticulocytes resulting from said first dose of EPO.
- 183. The method of claim 182, wherein said second dose of EPO is administered to said patient between six and twelve days after said first dose.
- 184. The method of claim 182, wherein said second dose of EPO is administered to said patient between six and ten days after said first dose.
- 185. The method of claim 182, wherein said second dose of EPO is administered to said patient seven days after said first dose.
- 186. A business method comprising the step of:
providing to a consumer an EPO dosing regimen that is a first dose of EPO followed by a second dose of EPO to a patient, wherein said second dose of EPO is administered to said patient at a time after said first dose that coincides with the production of reticulocytes resulting from said first dose of EPO.
- 187. The method of claim 186, wherein said EPO dose regimen comprises dosing one time per week with an effective amount of EPO.
- 188. The method of claim 187, wherein said effective amount of EPO comprises 40,000 IU/kg.
- 189. The method of claim 186, wherein said EPO dose regimen comprises dosing once every two weeks with an effective amount of EPO.
- 190. The method of claim 189, wherein said effective amount of EPO is selected from the group consisting of 80,000 IU/kg, 100,000 IU/kg, and 120,000 IU/kg.
- 191. A business method comprising the step of:
providing to a patient an EPO dosing regimen that is a first dose of EPO followed by a second dose of EPO to a patient, wherein said second dose of EPO is administered to said patient at a time after said first dose that coincides with the production of reticulocytes resulting from said first dose of EPO.
- 192. The method of claim 191, wherein said EPO dose regimen comprises dosing one time per week with an effective amount of EPO.
- 193. The method of claim 192, wherein said effective amount of EPO comprises 40,000 IU/kg.
- 194. The method of claim 191, wherein said EPO dose regimen comprises dosing once every two weeks with an effective amount of EPO.
- 195. The method of claim 194, wherein said effective amount of EPO is selected from the group consisting of 80,000 IU/kg, 100,000 IU/kg, and 120,000 IU/kg.
- 196. A business method comprising the step of:
providing a dosing regimen of EPO to a user or patient.
- 197. The method of claim 196, wherein said dosing regimen is once weekly.
- 198. The method of claim 196, wherein said dosing regimen is once every two weeks.
- 199. The method of claim 196 further comprising the step of:
providing EPO in conjunction with said providing a dosing regimen of EPO to a user or patient.
- 200. The method of claim 196, wherein said providing step comprises selling.
- 201. The method of claim 199, wherein said providing step comprises selling.
- 202. The method of claim 196, wherein said providing step is performed through the use of a computer system.
- 203. The method of claim 199, wherein said providing step is performed through the use of a computer system.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to provisional application Serial No. 60/133,418, filed May 11, 1999, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60133418 |
May 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09569612 |
May 2000 |
US |
Child |
10807451 |
Mar 2004 |
US |